Doha: Researchers in the United States: Researchers in the United States have reported promising results from an advanced clinical trial of a new immunotherapy that enables patients with aggressive bladder cancer to avoid surgical bladder removal.According to Qatar News Agency, the study, published in The Lancet Oncology, found that the treatment helped a number of patients remain cancer-free for more than two years, with most experiencing only limited side effects.The trial involved 115 patients with high-risk bladder cancer who received the new treatment, Crytostemogen Grenadineribvic, after conventional treatment with Bacillus Calmette-Guerin (BCG) had failed.The researchers found that 81 percent of patients did not require bladder removal surgery two years after receiving the treatment.They concluded that the new immunotherapy could offer a promising treatment option for patients with high-risk bladder cancer by delivering durable responses and reducing the need for surgical bladder removal.